# Novadiscovery

prospectively predicted the LDL-C outcomes of Merck's Phase 3 CORALreef Lipids trial using its jinkō causal-AI in-silico clinical trial platform, announced in November 2025 — a virtual patient "twin" simulating real-world physiology, disease progression and therapeutic response ahead of the trial's actual readout.

Source: https://en.bioecon.ru/companies/novadiscovery/
Updated: 2026-07-20

- Country: France

## Technologies

- [Patient digital twins & in-silico trials](https://en.bioecon.ru/technology/patient-digital-twins-in-silico-trials/)